Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
8.52
+0.01 (0.12%)
Aug 14, 2025, 11:50 AM - Market open
Y-mAbs Therapeutics Employees
Y-mAbs Therapeutics had 104 employees as of December 31, 2024. The number of employees increased by 4 or 4.00% compared to the previous year.
Employees
104
Change (1Y)
4
Growth (1Y)
4.00%
Revenue / Employee
$821,010
Profits / Employee
-$213,692
Market Cap
387.14M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 104 | 4 | 4.00% |
Dec 31, 2023 | 100 | -47 | -31.97% |
Dec 31, 2022 | 147 | -1 | -0.68% |
Dec 31, 2021 | 148 | 23 | 18.40% |
Dec 31, 2020 | 125 | 60 | 92.31% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
YMAB News
- 6 days ago - Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments - GlobeNewsWire
- 7 days ago - Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB - Business Wire
- 7 days ago - Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025 - GlobeNewsWire
- 9 days ago - SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics - GlobeNewsWire
- 2 months ago - Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline - GlobeNewsWire
- 2 months ago - Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting - GlobeNewsWire
- 3 months ago - Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025 - GlobeNewsWire